

Application Ser. No.: 10/786,483
Filing Date: February 25, 2004
Examiner: Chong, Yong Soo

Amendment Pursuant to 37 C.F.R. § 1.121

IN THE CLAIMS:

The claims set forth below with amendments as indicated will replace all prior versions and listing of claims in the application.

1. - 2. (canceled)

3. (currently amended) ~~The A combination according to claim 1, comprising wherein the compound of formula (I) as defined in claim 1 is 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine~~, or a pharmaceutically acceptable salt thereof and one or more products which activates dopaminergic neurotransmission in the brain.

4. (currently amended) The combination according to ~~claim 1~~claim 3, wherein the product which activates dopaminergic neurotransmission in the brain is chosen from the following compounds:
bromocriptine, cabergoline, adrogolide, BAM-1110, duodopa, levodopa, dopadose, CHF1512, PNU-95666, ropinirole, pramipexole, rotigotine, spheramine, TV1203, uridine, rasagiline, selegiline, SL340026, tolcapone and entacapone.

5. (currently amended) The combination according to ~~claim 1~~claim 3, wherein the product which activates dopaminergic neurotransmission in the brain is levodopa ~~and the CB1 antagonist is 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine.~~

6. (currently amended) The combination according to ~~claim 1~~claim 3, wherein the product which activates dopaminergic neurotransmission in the brain is ropinirole

Application Ser. No.: 10/786,483
Filing Date: February 25, 2004
Examiner: Chong, Yong Soo

and the CB1 antagonist is 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine).

7. (currently amended) The combination according to ~~claim 1~~ claim 3, wherein the product which activates dopaminergic neurotransmission in the brain is bromocriptine and the CB1 antagonist is 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine).
8. (currently amended) The combination according to ~~claim 1~~ claim 3, wherein the product which activates dopaminergic neurotransmission in the brain is pramipexole and the CB1 antagonist is 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine).
9. (currently amended) The combination according to ~~claim 1~~ claim 3, wherein the product which activates dopaminergic neurotransmission in the brain is rasagiline and the CB1 antagonist is 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine).
10. (currently amended) The combination according to ~~claim 1~~ claim 3, wherein the product which activates dopaminergic neurotransmission in the brain is entacapone and the CB1 antagonist is 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine).
11. (withdrawn-currently amended) A method of treating Parkinson's disease in a patient comprising administering to said patient a therapeutically effective amount of a combination of a product which activates dopaminergic neurotransmission in the brain and ~~one or more~~ CB1 antagonists of formula (I) as defined in ~~claim 1~~ 1 - [bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]-

Application Ser. No.: 10/786,483

Filing Date: February 25, 2004

Examiner: Chong, Yong Soo

azetidine or a pharmaceutically acceptable salt thereof, optionally in combination with a pharmaceutically acceptable carrier.

12. (withdrawn-currently amended) The method according to claim 11, wherein the compound of formula (I) ~~as defined in claim 1 is 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine,~~
or a pharmaceutically acceptable salt thereof product which activates dopaminergic neurotransmission in the brain is chosen from quinpirole, levodopa and C1-APB.

13. (withdrawn) The method according to claim 11, wherein the product which activates dopaminergic neurotransmission in the brain is chosen from the following compounds:

bromocriptine, cabergoline, adrogolide, BAM-1110, duodopa, levodopa, dopadose, CHF1512, PNU-95666, ropinirole, pramipexole, rotigotine, spheramine, TV1203, uridine, rasagiline, selegiline, SL340026, tolcapone and entacapone.

14. (withdrawn-currently amended) The method according to claim 11, wherein said product and ~~said compound of formula (I) as defined in claim 11-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine or a pharmaceutically acceptable salt thereof~~ are administered either simultaneously, separately or spread out over time.

15. (currently amended) A pharmaceutical composition comprising one or more products which activate dopaminergic neurotransmission in the brain and ~~one or more CB1-antagonist of formula (I) as defined in claim 11-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine or a pharmaceutically acceptable salt thereof~~ in combination with a compatible and pharmaceutically acceptable vehicle.

Application Ser. No.: 10/786,483
Filing Date: February 25, 2004
Examiner: Chong, Yong Soo

16. (currently amended) The pharmaceutical composition according to claim 15, wherein the ~~compound of formula (I) as defined in claim 1 is 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine~~, or a pharmaceutically acceptable salt thereof product which activates dopaminergic neurotransmission in the brain is chosen from quinpirole, levodopa and CI-APB.
17. (original) The pharmaceutical composition according to claim 15, wherein the product which activates dopaminergic neurotransmission in the brain is chosen from the following compounds:
bromocriptine, cabergoline, talipexole, adrogolide, BAM-1110, duodopa, levodopa, dopadose, CHF1512, PNU-95666, ropinirole, pramipexole, rotigotine, spheramine, TV1203, uridine, rasagiline, selegiline, SL340026, tolcapone and entacapone.
18. (currently amended) The pharmaceutical composition according to claim 15, wherein the product which activates dopaminergic neurotransmission in the brain is levodopa and the ~~CB1 antagonist is 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine~~.
19. (currently amended) The pharmaceutical composition according to claim 15, wherein the product which activates dopaminergic neurotransmission in the brain is ropinirole and the ~~CB1 antagonist is 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine~~.
20. (currently amended) The pharmaceutical composition according to claim 15, wherein the product which activates dopaminergic neurotransmission in the brain

Application Ser. No.: 10/786,483

Filing Date: February 25, 2004

Examiner: Chong, Yong Soo

~~is bromocriptine and the CB1 antagonist is 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine).~~

21. (currently amended) The pharmaceutical composition according to claim 15, wherein the product which activates dopaminergic neurotransmission in the brain is pramipexole ~~and the CB1 antagonist is 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine).~~
22. (currently amended) The pharmaceutical composition according to claim 15, wherein the product which activates dopaminergic neurotransmission in the brain is rasagiline ~~and the CB1 antagonist is 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine).~~
23. (currently amended) The pharmaceutical composition according to claim 15, wherein the product which activates dopaminergic neurotransmission in the brain is entacapone ~~and the CB1 antagonist is 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine).~~
24. (currently amended) The pharmaceutical composition according to claim 15, wherein ~~the CB1 antagonist of formula (I) as defined in claim 1~~ 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine is present in an amount of from about 0.1 mg to about 500 mg.
25. (new) The combination according to claim 3, wherein the product which activates dopaminergic neurotransmission in the brain is quinpirole.
26. (new) The combination according to claim 3, wherein the product which activates dopaminergic neurotransmission in the brain is C1-APB.

Application Ser. No.: 10/786,483
Filing Date: February 25, 2004
Examiner: Chong, Yong Soo

27. (new) The pharmaceutical composition according to claim 15, wherein the product which activates dopaminergic neurotransmission in the brain is quinpirole.
28. (new) The pharmaceutical composition according to claim 15, wherein the product which activates dopaminergic neurotransmission in the brain is C1-APB.